These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24902761)

  • 21. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma.
    Möller MG; Lewis JM; Dessureault S; Zager JS
    Int J Hyperthermia; 2008 May; 24(3):275-89. PubMed ID: 18393005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous leakage measurement during hyperthermic isolated limb perfusion.
    Daryanani D; Komdeur R; Ter Veen J; Nijhuis PH; Piers DA; Hoekstra HJ
    Ann Surg Oncol; 2001 Aug; 8(7):566-72. PubMed ID: 11508617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
    Thompson JF; Lai DT; Ingvar C; Kam PC
    Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
    Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
    Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
    Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
    Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma.
    Kettelhack C; Kraus T; Hupp T; Manner M; Schlag P
    Eur J Surg Oncol; 1990 Aug; 16(4):370-5. PubMed ID: 2379595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver.
    Huibers A; DePalo DK; Perez MC; Zager JS; Olofsson Bagge R
    Clin Exp Metastasis; 2024 Aug; 41(4):447-456. PubMed ID: 37843790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term functional outcome after hyperthermic isolated limb perfusion (HILP).
    Knorr C; Melling N; Goehl J; Drachsler T; Hohenberger W; Meyer T
    Int J Hyperthermia; 2008 Aug; 24(5):409-14. PubMed ID: 18608587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of isolated limb infusion with mild hyperthermia for melanoma.
    Thompson JF; Kam PC
    Int J Hyperthermia; 2008 May; 24(3):219-25. PubMed ID: 18393000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
    Padussis JC; Steerman SN; Tyler DS; Mosca PJ
    Int J Hyperthermia; 2008 May; 24(3):239-49. PubMed ID: 18393002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
    Nekkanti SS; Nusrath S; Jarang R; Rayani BK; Vamshi Krishna Y; Raju KVVN
    Melanoma Res; 2024 Jun; 34(3):276-279. PubMed ID: 38489577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: factors influencing toxicity.
    Duprat Neto JP; Mauro AC; Molina AS; Nishinari K; Zurstrassen CE; Costa OF; Belfort FA; Facure L; Fregnani JH
    ANZ J Surg; 2014 Sep; 84(9):677-82. PubMed ID: 22998400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.